To reduce tumor growth and enhance treatment efficacy, therapies that disrupt this inflammatory and anti-apoptotic signaling pathway can target the hyperactivation of NF-κB, a characteristic of many cancers, including skin, colon, and breast cancers [53]. The gene discussed is NFKB1; the disease is cancer.